phenylmethyl <2,3,9,9a-tetrahydro-2-(2-methylpropyl)-3-oxo-1-<(phenylmethoxy)carbonyl>-9-<(5,6,7,13-tetrahydro-5,13-dioxoquinazolino<3,2-a><1,4>benzodiazepin-7-yl)methyl>1H-imidazo<1,2-a>indol-9-yl>butanedioic acid ester | 103241-33-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 嘧啶二氮卓类
• 英文名称: phenylmethyl <2,3,9,9a-tetrahydro-2-(2-methylpropyl)-3-oxo-1-<(phenylmethoxy)carbonyl>-9-<(5,6,7,13-tetrahydro-5,13-dioxoquinazolino<3,2-a><1,4>benzodiazepin-7-yl)methyl>1H-imidazo<1,2-a>indol-9-yl>butanedioic acid ester
• 英文别名: phenylmethyl {2,3,9,9a-tetrahydro-2-(2-methylpropyl)-3-oxo-1-[(phenylmethoxy)carbonyl]-9-[(5,6,7,13-tetrahydro-5,13-dioxoquinazolino[3,2-a][1,4]benzodiazepin-7-yl)methyl]1H-imidazo[1,2-a]indol-9-yl}butanedioic acid ester；4-O-[(2S,3aR,4S)-4-[[(7S)-5,13-dioxo-6,7-dihydroquinazolino[3,2-a][1,4]benzodiazepin-7-yl]methyl]-2-(2-methylpropyl)-1-oxo-3-phenylmethoxycarbonyl-2,3a-dihydroimidazo[1,2-a]indol-4-yl] 1-O-benzyl butanedioate
• CAS: 103241-33-4
• 化学式: C₅₀H₄₅N₅O₉
• 分子量: 859.935
• InChiKey: AJNQGSWDZHHBBU-BAQPWROCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  64
• 可旋转键数：
  15
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  164
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  phenylmethyl <2,3,9,9a-tetrahydro-2-(2-methylpropyl)-3-oxo-1-<(phenylmethoxy)carbonyl>-9-<(5,6,7,13-tetrahydro-5,13-dioxoquinazolino<3,2-a><1,4>benzodiazepin-7-yl)methyl>1H-imidazo<1,2-a>indol-9-yl>butanedioic acid ester 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 23.0 ℃ 、344.73 kPa 条件下， 反应 4.5h， 以26%的产率得到mono<2,3,9,9a-tetrahydro-2-(2-methylpropyl)-3-oxo-9-<(5,6,7,13-tetrahydro-5,13-dioxoquinazolino<3,2-a><1,4>benzodiazepin-7-yl)methyl>1H-imidazo<1,2-a>indol-9-yl>butanedioic acid ester
  参考文献：
  名称：

  Cholecystokinin antagonists. Synthesis of asperlicin analogs with improved potency and water solubility

  摘要：

  Seventeen analogues of the selective, competitive cholecystokinin (CCK) antagonist asperlicin 1 were prepared. These compounds were tested as inhibitors of the binding of [125I]CCK to rat pancreas and guinea pig brain receptors. Compounds 4, 7, and 8 were more potent than asperlicin on the pancreatic CCK receptor. One analogue, 17, displayed potency equivalent to asperlicin on the pancreas CCK receptor and showed a marked improvement in aqueous solubility, thereby facilitating the use of this class of CCK antagonists in physiological and pharmacological studies.

  DOI：

  10.1021/jm00160a024
• 作为产物：
  描述：

  氯甲酸苄酯 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 生成 phenylmethyl <2,3,9,9a-tetrahydro-2-(2-methylpropyl)-3-oxo-1-<(phenylmethoxy)carbonyl>-9-<(5,6,7,13-tetrahydro-5,13-dioxoquinazolino<3,2-a><1,4>benzodiazepin-7-yl)methyl>1H-imidazo<1,2-a>indol-9-yl>butanedioic acid ester
  参考文献：
  名称：

  Cholecystokinin antagonists. Synthesis of asperlicin analogs with improved potency and water solubility

  摘要：

  Seventeen analogues of the selective, competitive cholecystokinin (CCK) antagonist asperlicin 1 were prepared. These compounds were tested as inhibitors of the binding of [125I]CCK to rat pancreas and guinea pig brain receptors. Compounds 4, 7, and 8 were more potent than asperlicin on the pancreatic CCK receptor. One analogue, 17, displayed potency equivalent to asperlicin on the pancreas CCK receptor and showed a marked improvement in aqueous solubility, thereby facilitating the use of this class of CCK antagonists in physiological and pharmacological studies.

  DOI：

  10.1021/jm00160a024

文献信息

• Cholecystokinin antagonists. Synthesis of asperlicin analogs with improved potency and water solubility
  作者：Mark G. Bock、Robert M. DiPardo、Kenneth E. Rittle、Ben E. Evans、Roger M. Freidinger、Daniel F. Veber、Raymond S. L. Chang、Tsing Bau Chen、Maureen E. Keegan、Victor J. Lotti

  DOI：10.1021/jm00160a024

  日期：1986.10

  Seventeen analogues of the selective, competitive cholecystokinin (CCK) antagonist asperlicin 1 were prepared. These compounds were tested as inhibitors of the binding of [125I]CCK to rat pancreas and guinea pig brain receptors. Compounds 4, 7, and 8 were more potent than asperlicin on the pancreatic CCK receptor. One analogue, 17, displayed potency equivalent to asperlicin on the pancreas CCK receptor and showed a marked improvement in aqueous solubility, thereby facilitating the use of this class of CCK antagonists in physiological and pharmacological studies.